ClinicalTrials.gg
CompletedNCT02265705Updated Sep 11, 2019Results posted

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)

A Phase 3 interventional study of Baricitinib and Placebo in Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Completed at 30 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-11.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
290
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing baricitinib in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, 1 of them phase 3. baricitinib · Arthritis, Rheumatoid.

Enrollment
12th of 23
290 · median 290
Started
2014
the only one that year
Phase 3
8 of 23
1 open now
Registered
11th of 23
by date
Lead sponsor
11 of 23
Eli Lilly and Company

Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, this one is the 12th largest by enrollment, is the only one that started in 2014, is one of 8 in phase 3, and was the 11th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 23 studies testing baricitinib in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About baricitinib

baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing baricitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as baricitinib in participants with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of adult-onset RA as defined by the ACR/European League Against Rheumatism (EULAR) 2010 Criteria for the Classification of RA.
  • Have moderately to severely active RA defined as the presence of at least 6/68 tender joints and at least 6/66 swollen joints.
  • Have a CRP (or hsCRP) measurement ≥ 6 mg/liter (L) based on the most recent data (if available).
  • Have had regular use of MTX for at least the 12 weeks prior to study entry at a dose that, in accordance with local clinical practice, is considered acceptable to adequately assess clinical response. The dose of MTX must have been a stable, unchanging oral dose of 7.5 to 25 mg/week (or the equivalent injectable dose) for at least the 8 weeks prior to study entry. The dose of MTX is expected to remain stable throughout the study and may be adjusted only for safety reasons.

Exclusion criteria

Exclusion Criteria:

  • Are currently receiving at doses >10 mg of prednisone per day (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of study entry or within 6 weeks of planned randomization.
  • Have started treatment with NSAIDs within 2 weeks of study entry or within 6 weeks of planned randomization or have been receiving an unstable dosing regimen of NSAIDs within 2 weeks of study entry or within 6 weeks of planned randomization.
  • Are currently receiving concomitant treatment with MTX, hydroxychloroquine, and sulfasalazine or combination of any 3 conventional disease modifying anti-rheumatic drugs (cDMARDs).
  • Are currently receiving or have received cDMARDs (for example, gold salts, cyclosporine, azathioprine, or any other immunosuppressives) other than MTX, hydroxychloroquine (up to 400 mg/day), or sulfasalazine (up to 3000 mg/day) within 8 weeks prior to study entry.
  • Have received leflunomide in the 12 weeks prior to study entry (or within 4 weeks prior to study entry if the standard 11 days of cholestyramine is used to washout leflunomide).
  • Have started a new physiotherapy treatment for RA in the 2 weeks prior to study entry.
  • Have ever received any biologic DMARD (such as tumor necrosis factor (TNF), interleukin-1, interleukin-6 (IL-6), or T-cell- or B-cell-targeted therapies).
  • Have received any parenteral corticosteroid administered by intramuscular or intravenous injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization or are anticipated to require parenteral injection of corticosteroids during the study.
  • Have had 3 or more joints injected with intraarticular corticosteroids or hyaluronic acid within 2 weeks prior to study entry or within 6 weeks prior to planned randomization.
  • Have a diagnosis of any systemic inflammatory condition other than RA such as, but not limited to, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic arthritis, active vasculitis or gout.
  • Have an estimated (eGFR) based on the most recent available serum creatinine using the Modification of Diet in Renal Disease (MDRD) method of \<40 milliliters/minute/1.73 meters squared (m\^2).
  • Have a history of chronic liver disease with the most recent available (AST) or alanine aminotransferase (ALT) >1.5 times the (ULN) or the most recent available total 1.5 times the ULN.
  • Have a current or recent (\<30 days prior to study entry) clinically serious viral, bacterial, fungal, or parasitic infection.
  • Have a history of active virus (HBV), virus (HCV), or (HIV).
  • Have had household contact with a person with active tuberculosis (TB) and did not receive appropriate and documented prophylaxis for TB.
  • Have evidence of active TB or have previously had evidence of active TB and did not receive appropriate and documented treatment.
  • Are pregnant or nursing at the time of study entry.
  • Are females of who do not agree to use 2 forms of highly effective when engaging in intercourse while enrolled in the study and for at least 28 days following the last dose of orally administered product.
  • Are males who do not agree to use 2 forms of highly effective birth control while engaging in sexual intercourse with female partners of childbearing potential while enrolled in the study and for at least 28 days following the last dose of orally administered investigational product.
  • Have previously been randomized in this study or any other study investigating baricitinib.
  • Have received prior treatment with an oral janus kinase inhibitor.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
290 participants (actual)

Study arms

  • Experimental
    Baricitinib

    4 milligrams (mg) baricitinib administered orally once a day for 52 weeks. Participants with renal impairment will receive 2 mg baricitinib orally once a day for 52 weeks. Participants will continue to take background methotrexate (MTX) therapy throughout study. Other background therapies, including non-steroidal anti-inflammatory drugs (NSAIDs) and low dose oral corticosteroids, are permitted during the study for participants who are on stable doses of these treatments at baseline.

    Drug: Baricitinib

  • Placebo comparator
    Placebo

    Placebo administered orally once a day through week 24. At week 24, participants will be given 4 mg or 2 mg (participants with renal impairment) baricitinib orally once a day through Week 52. Participants will continue to take background MTX therapy throughout study. Other background therapies, including NSAIDs and low dose oral corticosteroids, are permitted during the study for participants who are on stable doses of these treatments at baseline.

    Drug: Placebo

Interventions

  • Administered orally

    Also known as: LY3009104, INCB 028050

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving 20% Improvement in American College of Rheumatology Criteria (ACR20)

    ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100.

    Time frame: Week 12

Secondary outcomes

  1. Change From Baseline to Week 12 in the Health Assessment Questionnaire Disability Index (HAQ-DI) Score

    The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.

    Time frame: Baseline, Week 12

  2. Change From Baseline to Week 12 in Disease Activity Score Modified to Include the 28 Diarthroidal Joint Count (DAS28)-High Sensitivity C-Reactive Protein (hsCRP)

    Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.

    Time frame: Baseline, Week 12

  3. Proportion of Participants Achieving a Simplified Disease Activity Index (SDAI) Score < or Equal to 3.3

    SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Participant's Global Assessment of Disease Activity using VAS centimeters (cm), and Physician's Global Assessment of Disease Activity using VAS (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. An index-based definition of remission occurs with an SDAI score ≤3.3.

    Time frame: Week 12

  4. Median Duration of Morning Joint Stiffness in the 7 Days Prior to Week 12

    Participants recorded the duration of their morning joint stiffness (MJS) in hours and minutes into paper diaries daily. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. The average value across the 7 days preceding each visit was calculated. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.

    Time frame: Week 12

  5. Mean Severity of Morning Joint Stiffness in the 7 Days Prior to Week 12

    Participants rated the severity of their morning joint stiffness by selecting a number from 0 to 10 that best described their overall level of morning joint stiffness from the time they woke up, where 0 represents "no joint stiffness" and 10 represents "joint stiffness as bad as you can imagine". Participants reported their severity daily in paper diaries. The average value across the 7 days preceding each visit was calculated.

    Time frame: Week 12

  6. Mean Worst Tiredness Numeric Rating Scale (NRS) in the 7 Days Prior to Week 12

    Participants rated their tiredness by selecting a number from 0 to 10 that best described their worst tiredness during the last 24 hours, where 0 represents "no tiredness" and 10 represents "as bad as you can imagine". Participants reported their worst tiredness in paper diaries. The average value across the 7 days preceding each visit is calculated.

    Time frame: Week 12

  7. Mean Worst Pain NRS in the 7 Days Prior to Week 12

    Participants rated their joint pain by selecting a number from 0 to 10 that best described their worst joint pain during the last 24 hours, where 0 represents "no pain" and 10 represents "pain as bad as you can imagine". Participants reported their worst joint pain in daily paper diaries. The average value across the 7 days preceding each visit was calculated.

    Time frame: Week 12

07

Results

Posted Mar 13, 2019

Participant flow

Treatment Period Week 0-24
Participant flow — Treatment Period Week 0-24
MilestonePlacebo Treatment Period Week 0-244 Milligrams (mg) Baricitinib Treatment Period Week 0-24Rescue Treatment Period Week 16-52Placebo to Baricitinib Treatment Period Week 24 - 524 mg Baricitinib Treatment Period Week 24-52Placebo Follow-up Period4 mg Baricitinib Follow-up Period
Started14514500000
Received at least one dose of study drug14514500000
Rescued591700000
Completed13313600000
Not completed12900000
Withdrew: Adverse event3200000
Withdrew: Entry criteria not met1100000
Withdrew: Physician decision1000000
Withdrew: Withdrawal by subject7500000
Withdrew: Lack of efficacy0100000
Rescue Period
Participant flow — Rescue Period
MilestonePlacebo Treatment Period Week 0-244 Milligrams (mg) Baricitinib Treatment Period Week 0-24Rescue Treatment Period Week 16-52Placebo to Baricitinib Treatment Period Week 24 - 524 mg Baricitinib Treatment Period Week 24-52Placebo Follow-up Period4 mg Baricitinib Follow-up Period
Started00770000
Completed00740000
Not completed0030000
Withdrew: Withdrawal by subject0010000
Withdrew: Death0010000
Withdrew: Lack of efficacy0010000
Open Label Period
Participant flow — Open Label Period
MilestonePlacebo Treatment Period Week 0-244 Milligrams (mg) Baricitinib Treatment Period Week 0-24Rescue Treatment Period Week 16-52Placebo to Baricitinib Treatment Period Week 24 - 524 mg Baricitinib Treatment Period Week 24-52Placebo Follow-up Period4 mg Baricitinib Follow-up Period
Started0007412000
Completed0007211500
Not completed0002500
Withdrew: Adverse event0002200
Withdrew: Physician decision0000100
Withdrew: Withdrawal by subject0000200
Follow-up Period
Participant flow — Follow-up Period
MilestonePlacebo Treatment Period Week 0-244 Milligrams (mg) Baricitinib Treatment Period Week 0-24Rescue Treatment Period Week 16-52Placebo to Baricitinib Treatment Period Week 24 - 524 mg Baricitinib Treatment Period Week 24-52Placebo Follow-up Period4 mg Baricitinib Follow-up Period
Started00000258
Completed00000147
Not completed00000111
Withdrew: Sponsor decision0000016
Withdrew: Adverse event0000003
Withdrew: Physician decision0000001
Withdrew: Withdrawal by subject0000001

Outcome measures

PrimaryPercentage of Participants Achieving 20% Improvement in American College of Rheumatology Criteria (ACR20)

ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 20% Improvement in American College of Rheumatology Criteria (ACR20)
percentage of participantsPlaceboBaricitinib
Percentage of Participants Achieving 20% Improvement in American College of Rheumatology Criteria (ACR20)28.358.6
Statistical analysis
  • Placebo vs Baricitinib · Regression, Logistic · p = 0.001 · Odds ratio (or): 4.1 · 95% CI 2.5 to 6.9
SecondaryChange From Baseline to Week 12 in the Health Assessment Questionnaire Disability Index (HAQ-DI) Score

The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline to Week 12 in the Health Assessment Questionnaire Disability Index (HAQ-DI) Score
units on a scalePlaceboBaricitinib
Change From Baseline to Week 12 in the Health Assessment Questionnaire Disability Index (HAQ-DI) Score-0.35 ± 0.52-0.57 ± 0.54
Statistical analysis
  • Placebo vs Baricitinib · ANCOVA · p = 0.001 · Mean difference (final values): -0.20 · 95% CI -0.31 to -0.09
SecondaryChange From Baseline to Week 12 in Disease Activity Score Modified to Include the 28 Diarthroidal Joint Count (DAS28)-High Sensitivity C-Reactive Protein (hsCRP)

Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline to Week 12 in Disease Activity Score Modified to Include the 28 Diarthroidal Joint Count (DAS28)-High Sensitivity C-Reactive Protein (hsCRP)
units on a scalePlaceboBaricitinib
Change From Baseline to Week 12 in Disease Activity Score Modified to Include the 28 Diarthroidal Joint Count (DAS28)-High Sensitivity C-Reactive Protein (hsCRP)-0.94 ± 1.04-1.89 ± 1.14
Statistical analysis
  • Placebo vs Baricitinib · ANCOVA · p = 0.001 · Mean difference (final values): -1.02 · 95% CI -1.25 to -0.79
SecondaryProportion of Participants Achieving a Simplified Disease Activity Index (SDAI) Score < or Equal to 3.3

SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Participant's Global Assessment of Disease Activity using VAS centimeters (cm), and Physician's Global Assessment of Disease Activity using VAS (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. An index-based definition of remission occurs with an SDAI score ≤3.3.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Proportion of Participants Achieving a Simplified Disease Activity Index (SDAI) Score < or Equal to 3.3
ParticipantsPlaceboBaricitinib
Proportion of Participants Achieving a Simplified Disease Activity Index (SDAI) Score < or Equal to 3.302
Statistical analysis
  • Placebo vs Baricitinib · Difference in response rate: 1.4 · 95% CI -0.5 to 3.3
SecondaryMedian Duration of Morning Joint Stiffness in the 7 Days Prior to Week 12

Participants recorded the duration of their morning joint stiffness (MJS) in hours and minutes into paper diaries daily. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. The average value across the 7 days preceding each visit was calculated. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.

Time frame:
Week 12
Reported as:
Median · minutes
Median Duration of Morning Joint Stiffness in the 7 Days Prior to Week 12
minutesPlaceboBaricitinib
Median Duration of Morning Joint Stiffness in the 7 Days Prior to Week 1247.6 (30.0 to 67.9)24.3 (15.0 to 30.6)
Statistical analysis
  • Placebo vs Baricitinib · Wilcoxon (Mann-Whitney) · p = 0.004 · Median difference (final values): -12.9 · 95% CI -28.0 to -2.9
SecondaryMean Severity of Morning Joint Stiffness in the 7 Days Prior to Week 12

Participants rated the severity of their morning joint stiffness by selecting a number from 0 to 10 that best described their overall level of morning joint stiffness from the time they woke up, where 0 represents "no joint stiffness" and 10 represents "joint stiffness as bad as you can imagine". Participants reported their severity daily in paper diaries. The average value across the 7 days preceding each visit was calculated.

Time frame:
Week 12
Reported as:
Mean · units on a scale
Mean Severity of Morning Joint Stiffness in the 7 Days Prior to Week 12
units on a scalePlaceboBaricitinib
Mean Severity of Morning Joint Stiffness in the 7 Days Prior to Week 124.3 ± 2.33.5 ± 2.1
Statistical analysis
  • Placebo vs Baricitinib · ANCOVA · p = 0.002 · Mean difference (final values): -0.8 · 95% CI -1.2 to -0.3
SecondaryMean Worst Tiredness Numeric Rating Scale (NRS) in the 7 Days Prior to Week 12

Participants rated their tiredness by selecting a number from 0 to 10 that best described their worst tiredness during the last 24 hours, where 0 represents "no tiredness" and 10 represents "as bad as you can imagine". Participants reported their worst tiredness in paper diaries. The average value across the 7 days preceding each visit is calculated.

Time frame:
Week 12
Reported as:
Mean · units on a scale
Mean Worst Tiredness Numeric Rating Scale (NRS) in the 7 Days Prior to Week 12
units on a scalePlaceboBaricitinib
Mean Worst Tiredness Numeric Rating Scale (NRS) in the 7 Days Prior to Week 124.4 ± 2.03.7 ± 1.9
Statistical analysis
  • Placebo vs Baricitinib · ANCOVA · p = 0.001 · Mean difference (final values): -0.8 · 95% CI -1.2 to -0.4
SecondaryMean Worst Pain NRS in the 7 Days Prior to Week 12

Participants rated their joint pain by selecting a number from 0 to 10 that best described their worst joint pain during the last 24 hours, where 0 represents "no pain" and 10 represents "pain as bad as you can imagine". Participants reported their worst joint pain in daily paper diaries. The average value across the 7 days preceding each visit was calculated.

Time frame:
Week 12
Reported as:
Mean · units on a scale
Mean Worst Pain NRS in the 7 Days Prior to Week 12
units on a scalePlaceboBaricitinib
Mean Worst Pain NRS in the 7 Days Prior to Week 125.0 ± 1.84.1 ± 1.9
Statistical analysis
  • Placebo vs Baricitinib · ANCOVA · p = 0.001 · Mean difference (final values): -0.9 · 95% CI -1.3 to -0.5

Adverse events

Collected over Start of treatment to end of study (Up To 52 Weeks). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Treatment Period Week 0-240/145 (0%)4/145 (2.8%)72/145 (49.7%)
4 Milligrams (mg) Baricitinib Treatment Period Week 0-240/145 (0%)4/145 (2.8%)94/145 (64.8%)
Rescue Treatment Period Week 16-521/77 (1.3%)3/77 (3.9%)38/77 (49.4%)
Placebo to Baricitinib Treatment Period Week 24 - 520/74 (0%)7/74 (9.5%)31/74 (41.9%)
4 mg Baricitinib Treatment Period Week 24-520/120 (0%)3/120 (2.5%)41/120 (34.2%)
Placebo Follow-up Period0/2 (0%)0/2 (0%)0/2 (0%)
4 mg Baricitinib Follow-up Period0/58 (0%)1/58 (1.7%)3/58 (5.2%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventPlacebo Treatment Period Week 0-244 Milligrams (mg) Baricitinib Treatment Period Week 0-24Rescue Treatment Period Week 16-52Placebo to Baricitinib Treatment Period Week 24 - 524 mg Baricitinib Treatment Period Week 24-52Placebo Follow-up Period4 mg Baricitinib Follow-up Period
Subarachnoid haemorrhageInjury, poisoning and procedural complications0/1450/1450/770/740/1200/21/58
Intracranial aneurysmNervous system disorders0/1450/1450/770/740/1200/21/58
Angina unstableCardiac disorders0/1450/1450/771/740/1200/20/58
EnteritisGastrointestinal disorders0/1450/1450/771/740/1200/20/58
Lung infectionInfections and infestations0/1450/1450/771/740/1200/20/58
PneumoniaInfections and infestations0/1450/1451/771/740/1200/20/58
Viral infectionInfections and infestations0/1450/1450/771/740/1200/20/58
Spinal disorderMusculoskeletal and connective tissue disorders0/1450/1450/771/740/1200/20/58
Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1450/1450/771/740/1200/20/58
Renal tubular acidosisRenal and urinary disorders0/1450/1450/771/740/1200/20/58
Most frequent other events
Showing 10 of 35
Most frequent other events
EventPlacebo Treatment Period Week 0-244 Milligrams (mg) Baricitinib Treatment Period Week 0-24Rescue Treatment Period Week 16-52Placebo to Baricitinib Treatment Period Week 24 - 524 mg Baricitinib Treatment Period Week 24-52Placebo Follow-up Period4 mg Baricitinib Follow-up Period
Upper respiratory tract infectionInfections and infestations22/14528/1457/775/7411/1200/20/58
Urinary tract infectionInfections and infestations5/14513/14510/774/743/1200/20/58
HyperlipidaemiaMetabolism and nutrition disorders8/14516/1456/773/749/1200/20/58
AnaemiaBlood and lymphatic system disorders14/14512/1450/770/740/1200/20/58
NasopharyngitisInfections and infestations6/14510/1456/774/744/1200/20/58
Benign prostatic hyperplasiaReproductive system and breast disorders0/1450/1450/770/221/140/20/58
Blood creatine phosphokinase increasedInvestigations0/1459/1455/775/742/1200/20/58
ArthralgiaMusculoskeletal and connective tissue disorders9/1450/1452/771/743/1200/23/58
CoughRespiratory, thoracic and mediastinal disorders2/1459/1453/772/741/1200/20/58
HeadacheNervous system disorders8/1455/1450/770/740/1200/20/58

Baseline characteristics

Modified Intent-to-Treat (mITT) population includes all randomized participants who received at least one dose of the study drug.

Age, Continuous
Age, Continuous(years)PlaceboBaricitinibTotal
Mean48.9 ± 12.749.5 ± 10.649.2 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBaricitinibTotal
Female106127233
Male391857
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboBaricitinibTotal
Hispanic or Latino000
Not Hispanic or Latino115116231
Unknown or Not Reported302959
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboBaricitinibTotal
American Indian or Alaska Native156
Asian115116231
Native Hawaiian or Other Pacific Islander000
Black or African American303
White262450
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)PlaceboBaricitinibTotal
Argentina222143
China115116231
Brazil8816
Duration of Rheumatoid Arthritis
Duration of Rheumatoid Arthritis(years)PlaceboBaricitinibTotal
Mean9.1 ± 7.010.7 ± 8.39.9 ± 7.7
Tender Joint Count of 68 Evaluable Joints
Tender Joint Count of 68 Evaluable Joints(Tender Joints)PlaceboBaricitinibTotal
Mean25.2 ± 14.723.3 ± 13.624.2 ± 14.2
Swollen Joint Count of 66 Evaluable Joints
Swollen Joint Count of 66 Evaluable Joints(Swollen Joints)PlaceboBaricitinibTotal
Mean14.8 ± 9.514.6 ± 8.614.7 ± 9.1

1 further baseline measures are reported on the registry.

08

Study locations

30 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ciudad Autonoma de Buenos Aire, C1015ABO, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ciudad Autonoma de Buenos Aire, C1431FWO, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ciudad Autonoma de Buenos Aire, C1440AAD, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rosario, S2000CFJ, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Juan, J5402DIL, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Miguel De Tucuman, T4000AXL, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sao Paulo, 04266-010, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    São Paulo, 01244-030, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beijing, 100029, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beijing, 100044, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bengbu, 233004, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Changsha, 410008, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Changsha, 410011, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chengdu, 610041, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guangzhou, 510080, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hefei, 230001, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hefei, 230022, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jinan, 250012, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kunming, 650032, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nanjing, 210029, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ningbo, 315010, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pingxiang, 337055, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shanghai, 200001, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shanghai, 200032, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shanghai, 200052, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shantou, 515041, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tianjin, 300052, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wuhan City, 430030, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yancheng, 224005, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    ZhuZhou, 412007, China
09

References and documents

Publications

  • Taylor PC, Takeuchi T, Burmester GR, Durez P, Smolen JS, Deberdt W, Issa M, Terres JR, Bello N, Winthrop KL. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022 Mar;81(3):335-343. doi: 10.1136/annrheumdis-2021-221276. Epub 2021 Oct 27. PubMed 34706874 ↗
  • Yang Y, Xu J, Xu J, Li X, Hu J, Li X, Zhang X, He D, Bao C, Li Z, Wang G, Zerbini CAF, Spindler AJ, Kannowski CL, Wu H, Ji F, Zhan L, Liu M, Li Z. Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study. Ther Adv Musculoskelet Dis. 2021 Apr 20;13:1759720X211006964. doi: 10.1177/1759720X211006964. eCollection 2021. PubMed 33959198 ↗
  • Li ZG, Hu JK, Li XP, Yang Y, Li XF, Xu JH, Zhang X, Xu J, Bao CD, He DY, Li ZJ, Wang GC, Zuo XX, Liu Y, Xiao ZY, Chen JW, Xin XF, Li JY, Jiang LD, Liu MR, Ji F, Li CG. Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE. Adv Ther. 2021 Jan;38(1):772-781. doi: 10.1007/s12325-020-01572-y. Epub 2020 Nov 25. PubMed 33237533 ↗
  • Yang Y, Li XF, Zhang X, Bao CD, Hu JK, Xu JH, Li XP, Xu J, He DY, Li ZJ, Wang GC, Wu HJ, Ji F, Zhan LJ, Zerbini CAF, Li ZG. Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE. Rheumatol Ther. 2020 Dec;7(4):851-866. doi: 10.1007/s40744-020-00231-6. Epub 2020 Sep 2. PubMed 32876903 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of May 2017 and a completion of May 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2019, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2014
First posted
Oct 16, 2014
Start
Oct 2014
Primary completionActual
May 2017
CompletionActual
May 2017
Results first posted
Mar 13, 2019
Last update
Sep 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02265705
Responsible party
Sponsor
First posted
Oct 16, 2014
Start date
Oct 2014
Primary completion
May 2017
Completion
May 2017
Results posted
Mar 13, 2019
Last update
Sep 11, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion